160 related articles for article (PubMed ID: 25173798)
1. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
Wu MY; Fu J; Xiao X; Wu J; Wu RC
Cancer Lett; 2014 Nov; 354(2):311-9. PubMed ID: 25173798
[TBL] [Abstract][Full Text] [Related]
2. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
Witt AE; Lee CW; Lee TI; Azzam DJ; Wang B; Caslini C; Petrocca F; Grosso J; Jones M; Cohick EB; Gropper AB; Wahlestedt C; Richardson AL; Shiekhattar R; Young RA; Ince TA
Oncogene; 2017 Mar; 36(12):1707-1720. PubMed ID: 27694895
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Injinari N; Amini-Farsani Z; Yadollahi-Farsani M; Teimori H
Life Sci; 2021 Mar; 269():119027. PubMed ID: 33453248
[TBL] [Abstract][Full Text] [Related]
4. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
Caslini C; Hong S; Ban YJ; Chen XS; Ince TA
Oncogene; 2019 Sep; 38(39):6599-6614. PubMed ID: 31375747
[TBL] [Abstract][Full Text] [Related]
5. Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
Lin L; Jiang H; Huang M; Hou X; Sun X; Jiang X; Dong X; Sun X; Zhou B; Qiao H
Oncol Rep; 2015 Aug; 34(2):663-72. PubMed ID: 26035691
[TBL] [Abstract][Full Text] [Related]
6. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
[TBL] [Abstract][Full Text] [Related]
7. miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.
Zhao Q; Li S; Li N; Yang X; Ma S; Yang A; Zhang H; Yang S; Mao C; Xu L; Gao T; Yang X; Zhang H; Jiang Y
J Cell Biochem; 2017 Dec; 118(12):4617-4627. PubMed ID: 28485501
[TBL] [Abstract][Full Text] [Related]
8. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
[TBL] [Abstract][Full Text] [Related]
9. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Mohammady M; Ghetmiri SI; Baharizade M; Morowvat MH; Torabi S
Curr Pharm Biotechnol; 2019; 20(8):665-673. PubMed ID: 31244419
[TBL] [Abstract][Full Text] [Related]
11. [Efflect of miR-34a-Tangeted Regulation of HDACI on Apoptosis of AML Cells].
Wen C; Xie YK; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):790-795. PubMed ID: 31204933
[TBL] [Abstract][Full Text] [Related]
12. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer.
Jeon HS; Lee SY; Lee EJ; Yun SC; Cha EJ; Choi E; Na MJ; Park JY; Kang J; Son JW
Lung Cancer; 2012 May; 76(2):171-6. PubMed ID: 22078727
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin.
Shen Q; Yao Q; Sun J; Feng L; Lu H; Ma Y; Liu L; Wang F; Li J; Yue Y; Jin H; Wang X
FEBS Lett; 2014 Jan; 588(1):184-91. PubMed ID: 24316511
[TBL] [Abstract][Full Text] [Related]
15. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.
Lin X; Chen W; Wei F; Zhou BP; Hung MC; Xie X
Theranostics; 2017; 7(19):4805-4824. PubMed ID: 29187905
[No Abstract] [Full Text] [Related]
17. Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
Lei Y; Liu L; Zhang S; Guo S; Li X; Wang J; Su B; Fang Y; Chen X; Ke H; Tao W
Mol Cancer; 2017 Nov; 16(1):170. PubMed ID: 29126425
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
19. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.
Yang S; Li Y; Gao J; Zhang T; Li S; Luo A; Chen H; Ding F; Wang X; Liu Z
Oncogene; 2013 Sep; 32(36):4294-303. PubMed ID: 23001043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
